Tandem Diabetes Care (NASDAQ:TNDM) Issues Quarterly Earnings Results

Tandem Diabetes Care (NASDAQ:TNDM) issued its quarterly earnings data on Thursday. The medical device company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.16, FiscalAI reports. The firm had revenue of $247.22 million for the quarter, compared to analysts’ expectations of $240.41 million. Tandem Diabetes Care had a negative net margin of 9.20% and a negative return on equity of 53.10%. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.66) earnings per share.

Here are the key takeaways from Tandem Diabetes Care’s conference call:

• Tandem reported strong Q1 results with more than 29,000 pump shipments and $247 million in sales, and management is reaffirming 2026 guidance.
• The company has begun its PayGo pharmacy rollout, achieving ~40% formulary coverage early and <5% initial pharmacy ordering, a strategic shift management says will raise ASPs and margins as execution scales.
• Product momentum accelerated: Mobi now supports Android in the U.S., Control‑IQ+ cleared for use in pregnancy (first AID cleared for pregnancy in the U.S.), Libre 3 Plus and Dexcom G7 integrations planned, international Mobi launch in Q2, and a Mobi Tubeless 510(k) filing and a pivotal fully closed‑loop study are on track.
• Infusion set supplier shortages created modest supply‑sales pressure and meaningful customer impact for affected SKUs, with the company expecting disruption to persist into Q2 and some $3M–$4M timing headwinds from the international go‑direct transition.
• Margins and balance sheet strengthened: Q1 non‑GAAP gross margin was 55% (a Q1 record), adjusted EBITDA improved, the company generated $5M free cash flow and ended the quarter with $570M in cash (including $276M net proceeds from convertible debt), supporting execution of strategy.

Tandem Diabetes Care Price Performance

TNDM opened at $15.48 on Friday. The company’s 50 day simple moving average is $21.32 and its 200-day simple moving average is $20.33. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $29.65. The stock has a market capitalization of $1.06 billion, a P/E ratio of -11.06 and a beta of 1.64. The company has a debt-to-equity ratio of 2.00, a current ratio of 2.55 and a quick ratio of 2.02.

Key Stories Impacting Tandem Diabetes Care

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q1 revenue came in at $247.2 million, above consensus, while adjusted EPS of -$0.30 beat the expected -$0.46, signaling better-than-expected execution. Tandem Diabetes’s (NASDAQ:TNDM) Q1 CY2026: Beats On Revenue, Stock Jumps 10.9%
• Positive Sentiment: Management highlighted record first-quarter pump shipments, sales, and gross margin, along with margin expansion and pipeline progress, which supports the view that the business model is improving. Tandem Diabetes Care Announces First Quarter 2026 Financial Results
• Positive Sentiment: TD Cowen reaffirmed a Buy rating and kept its $28 price target, reinforcing bullish sentiment from analysts after the earnings release. Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained
• Neutral Sentiment: The company also reaffirmed full-year 2026 guidance, which suggests management is not seeing a major near-term change to its outlook.
• Negative Sentiment: Despite the beat, Tandem still posted a quarterly loss and remained unprofitable, so investors may stay focused on whether revenue growth and margin gains can translate into sustained earnings improvement.

Wall Street Analysts Forecast Growth

TNDM has been the topic of several research analyst reports. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $25.00 price objective (up from $18.00) on shares of Tandem Diabetes Care in a research note on Friday, January 9th. Mizuho set a $24.00 price target on shares of Tandem Diabetes Care in a research note on Friday. Rothschild & Co Redburn set a $45.00 price target on shares of Tandem Diabetes Care in a research note on Friday, April 24th. Lake Street Capital raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research note on Monday, February 23rd. Finally, Truist Financial raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and increased their price target for the company from $27.00 to $35.00 in a research note on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $30.16.

Hedge Funds Weigh In On Tandem Diabetes Care

Several large investors have recently bought and sold shares of the business. Corient Private Wealth LLC acquired a new position in Tandem Diabetes Care in the fourth quarter valued at approximately $346,000. Mercer Global Advisors Inc. ADV acquired a new position in Tandem Diabetes Care in the fourth quarter valued at approximately $248,000. EP Wealth Advisors LLC acquired a new position in Tandem Diabetes Care in the fourth quarter valued at approximately $219,000. Wellington Management Group LLP acquired a new position in Tandem Diabetes Care in the fourth quarter valued at approximately $2,161,000. Finally, Man Group plc acquired a new position in Tandem Diabetes Care in the fourth quarter valued at approximately $281,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.